Literature DB >> 11177594

A functional hierarchy among the CD34+ hematopoietic cells based on in vitro proliferative and differentiative potential of AC133+CD34(bright) and AC133(dim/)-CD34+ human cord blood cells.

E Goussetis1, M Theodosaki, G Paterakis, J Peristeri, D Petropoulos, V Kitra, C Papassarandis, S Graphakos.   

Abstract

The 5-transmembrane receptor AC133 is expressed on a subpopulation of human hematopoietic cells that includes the CD34(bright) cells. We evaluated the developmental potential of AC133+CD34(bright) and AC133(dim/-)CD34+ cells isolated from 5 cord blood (CB) samples by studying the in vitro proliferative and differentiative potential of each population in both progenitor and mature cell expansion cultures. Seven-day culture of AC133+CD34(bright) cells with a cytokine combination favoring primitive progenitor cells causes a significant increase in CD34+, CFU-C and noncycling stem/progenitor cells HPP-Q (High Proliferative Potential-Quiescent), whereas culture of AC133(dim/-)CD34+ cells shows a limited increase in committed progenitor cells only. HPP-Q cells were not found in freshly isolated AC133(dim/-)CD34+ nor in expanded CD34+ cells derived from AC133(dim/-)CD34+ cells. No statistically significant difference was observed between the 1-week expanded AC133+ and the initial AC133+CD34(bright) cells regarding their clonogenic efficiency (CE), while expanded CD34+ cells derived from AC133(dim/-)CD34+ cells exhibited a decreased CE. Subexpansion of the reselected AC133+ derived from AC133+CD34(bright) cells reveals a further increase of stem/progenitor cells and the 14-day expanded AC133+ cells reveal an unchanged CE. Subexpansion of reselected 7-day CD34+ cells derived from AC133(dim/-)CD34+ cells was not possible. Culture of AC133+CD34(bright) cells in cytokines that favor megakaryopoiesis or erythropoiesis resulted in a significant expansion of CD41+ and CD71+ cells, respectively; AC133(dim/-)CD34+, in comparison, showed a limited potential to megakaryocytic differentiation and a decreased production of erythroid cells. Our data indicate that early high proliferating stem/progenitor cells and early committed progenitors are present in AC133+CD34(bright) cells, but not in AC133(dim/-)CD34+ cells; the latter represent late committed progenitors with limited proliferative potential.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11177594     DOI: 10.1089/152581600750062255

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  10 in total

1.  Comparative analysis of proliferative potential and clonogenicity of MACS-immunomagnetic isolated CD34+ and CD133+ blood stem cells derived from a single donor.

Authors:  D Freund; J Oswald; S Feldmann; G Ehninger; D Corbeil; M Bornhäuser
Journal:  Cell Prolif       Date:  2006-08       Impact factor: 6.831

Review 2.  Reviewing and updating the major molecular markers for stem cells.

Authors:  Raquel Calloni; Elvira Alicia Aparicio Cordero; João Antonio Pêgas Henriques; Diego Bonatto
Journal:  Stem Cells Dev       Date:  2013-01-22       Impact factor: 3.272

3.  Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.

Authors:  Mark M Painter; Thomas D Zaikos; Kathleen L Collins
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

4.  CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients.

Authors:  Elisabet Björklund; Astrid Gruber; Joanna Mazur; Anna Mårtensson; Mona Hansson; Anna Porwit
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

5.  Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial.

Authors:  Philip Noel Newsome; Richard Fox; Andrew L King; Darren Barton; Nwe-Ni Than; Joanna Moore; Christopher Corbett; Sarah Townsend; James Thomas; Kathy Guo; Diana Hull; Heather A Beard; Jacqui Thompson; Anne Atkinson; Carol Bienek; Neil McGowan; Neil Guha; John Campbell; Dan Hollyman; Deborah Stocken; Christina Yap; Stuart John Forbes
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-11-07

6.  Regeneration of rat corpora cavernosa tissue by transplantation of CD133+ cells derived from human bone marrow and placement of biodegradable gel sponge sheet.

Authors:  Shogo Inoue; Katsutoshi Miyamoto; Shunsuke Shinmei; Koichi Shoji; Jun Teishima; Kazuhiro Sentani; Wataru Yasui; Akio Matsubara
Journal:  Asian J Androl       Date:  2017 Mar-Apr       Impact factor: 3.285

7.  Human cord blood-derived AC133+ progenitor cells preserve endothelial progenitor characteristics after long term in vitro expansion.

Authors:  Branislava Janic; Austin M Guo; A S M Iskander; Nadimpalli Ravi S Varma; Alfonso G Scicli; Ali S Arbab
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

8.  Characteristics of myeloid differentiation and maturation pathway derived from human hematopoietic stem cells exposed to different linear energy transfer radiation types.

Authors:  Satoru Monzen; Hironori Yoshino; Kiyomi Kasai-Eguchi; Ikuo Kashiwakura
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

9.  Absence of a relationship between immunophenotypic and colony enumeration analysis of endothelial progenitor cells in clinical haematopoietic cell sources.

Authors:  Olga Tura; G Robin Barclay; Huw Roddie; John Davies; Marc L Turner
Journal:  J Transl Med       Date:  2007-07-18       Impact factor: 5.531

10.  A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis.

Authors:  Lisa M Ebert; Lih Y Tan; M Zahied Johan; Kay Khine Myo Min; Michaelia P Cockshell; Kate A Parham; Kelly L Betterman; Paceman Szeto; Samantha Boyle; Lokugan Silva; Angela Peng; YouFang Zhang; Andrew Ruszkiewicz; Andrew C W Zannettino; Stan Gronthos; Simon Koblar; Natasha L Harvey; Angel F Lopez; Mark Shackleton; Claudine S Bonder
Journal:  Angiogenesis       Date:  2016-06-23       Impact factor: 9.596

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.